NEW YORK (TheStreet) -- Repros Therapeutics  (RPRX) stock is falling 26.09% to $1.77 on heavy volume trading on Tuesday, after the FDA expressed concerns about the company's reproductive drug.

The FDA recommended that Repros conduct an additional Phase 3 study into its enclomiphene drug. The drug is intended to treat a reproductive disorder, known as secondary hypogonadism, in overweight men. 

The FDA also said it was concerned regarding the study's entry criteria, titration and bioanalytical method validation.

"We are disappointed that the FDA has taken this position without the benefit of an advisory committee recommendation," Repros CEO Joseph Podolski said in a statement. "We plan to work closely with the agency to gain more information to determine the appropriate next steps regarding the enclomiphene application."

So far today, 4.13 million shares of Repros have traded, versus its 30-day average of 1.45 million shares.

RPRX Chart

 

RPRX Chart RPRX data by YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.

More from Markets

IBM Shares Jump After Beating Earnings and Guidance Expectations

IBM Shares Jump After Beating Earnings and Guidance Expectations

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

Tesla's Biggest Near-Term Headwind, According to Analyst

Tesla's Biggest Near-Term Headwind, According to Analyst

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

New Trend for Gap Stock Is Down

New Trend for Gap Stock Is Down